KAUTI
Articles
- Page Path
- HOME > Korean J Urogenit Tract Infect Inflamm > Volume 2(1); 2007 > Article
- Original Article Multicenter Clinical Outcome of Gatifloxacin for Chronic Prostatitis (NIH Category II or IIIa) in Korea
- Sang Don Lee, Seung Ju Lee, Tae Kon Hwang, Duck Ki Yoon, Kyu Sung Lee, Luck Hee Sung, Myung Soo Choo, Bong Suk Shim, In Rae Cho, Min Eui Kim, Soo Bang Ryu, Chul Sung Kim, Young Gon Kim, Chun Il Kim, Hyun Yul Rhew, Yong-Hyun Cho
-
Multicenter Clinical Outcome of Gatifloxacin for Chronic Prostatitis (NIH Category II or IIIa) in Korea - , , , , , , , , , , , , , , ,
-
Urogenital Tract Infection 2007;2(1):53-60.
Published online: May 31, 2007
From the Department of Urology, 1Pusan National University Hospital, 2Korean Association of Urogenital Tract Infection and flammation, 3Daniel Urolgy Clinic, 4Kangnam St. Mary's Hospital, The Catholic University of Korea, 5Guro Hospital, Korea University, 6Samsung Medical Center, Sunkyunkwan University, 7Sanggye Paik Hospital, Inje University, 8Asan Medical Center, Ulsan University, 9Dongdaemun Hospital, Ewha Womans University, 10Ilsan Paik Hospital, Inje University, 11Bucheon Hospital, Soonchunhyang University, 12Chonnam National University Hospital, 13Chosun University Hospital, 14Chonbuk National University Hospital, 15Dongsan Medical Center, Keimyung university, 16Kosin Medical Center, Kosin university, 17St. Mary's Hospital, The Catholic University of Korea, Korea
- 15 Views
- 0 Download
- 0 Crossref
- 0 Scopus
Abstract
"Purpose: The objective of this study was to investigate the efficacy and safety of gatifloxacin for patients with chronic prostatitis (NIH category II or IIIa) in Korean urologic practice. Materials and Methods: A total of 16 outpatient urology clinics at tertiary care medical centers in Korea participated. Gatifloxacin (400 mg/day) treatment (S.D.) of 149 patients (20 patients with category II and 129 patients with category IIIa) with prostatitis (mean age 45.8±13.3 years) was carried out for 41.7 (33.1) days. A 4-glass test according to Meares and Stamey or two glass test was carried out at study entry and one month after the end of treatment. Clinical response, safety and bacteriological response were assessed before treatment (within 48 hours of initiation of the study medication) and at one month after treatment completion. Results: In a otal of 149 patients, the total NIH-CPSI score was significantly reduced from 20.5 to 10.0 (response rate 86.7%; 95% CI 80.2-93.2%) (p<0.05). Sub-scores of pain, urinary symptoms and impact on the quality of life were also significantly reduced from 8.9 to 3.8 (response rate 83.8%; 95% CI 76.8-90.9%), from 4.2 to 2.0 (response rate 73.3%; 95% CI 64.9-81.8%) and from 7.4 to 4.2 (response rate 79.0%; 95% CI 71.3-86.8%), respectively (p<0.05). In terms of the overall clinical efficacy assessment by investigators, out of 149 patients with prostatitis, 71.2% were assessed to be responders. Bacteriological studies in expressed prostatic secretion (EPS) or post prostate massage urine (VB3) at 1 month after treatment completion demonstrated that the overall eradication rates of pathogens was 85% and the pyuria (≥10 WBC/HPF) rates in the NIH category II and IIIa were 35% and 18.6%, respectively (overall rate 20.8%). There were 16.1% of patients that presented with some adverse events considered by investigators to be related to the drug. The majority of adverse events were considered to be of mild (87.5%) or moderate (8.3%) intensity. Conclusions: These results suggest that gatifloxacin in Korean urologic practice is well tolerated and improves the clinical outcomes in the patientswith chronic prostatitis (NIH category II or IIIa)."
Cite
